Kinnate Biopharma Inc. (KNTE) Research

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.

Market snapshot

Symbol
KNTE
Price
$2.65
Day change
-0.38%
Market cap
$125.0M
P/E ratio
-1.10x
52-week range
1.04-7.185
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$30.00

Peer companies

  • Aadi Bioscience, Inc. (AADI)
  • aTyr Pharma, Inc. (ATYR)
  • Decibel Therapeutics, Inc. (DBTX)
  • Graybug Vision, Inc. (GRAY)
  • NGM Biopharmaceuticals, Inc. (NGM)
  • Pardes Biosciences, Inc. (PRDS)
  • Paratek Pharmaceuticals, Inc. (PRTK)
  • RVL Pharmaceuticals plc (RVLP)

Recent insider activity

  • Tananbaum James B. — D-Return (40501 shares) on 2024-04-03
  • Tananbaum James B. — D-Return (20250 shares) on 2024-04-03
  • Tananbaum James B. — D-Return (520711 shares) on 2024-04-03
  • Farzan Nima — D-Return (750000 shares) on 2024-04-03
  • Farzan Nima — D-Return (275000 shares) on 2024-04-03

Open Kinnate Biopharma Inc. (KNTE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.